The leukotriene signaling pathway: a druggable target in Alzheimer's disease
| Autor: | Julia Marschallinger, Johanna Michael, Ludwig Aigner |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Leukotrienes Amyloid beta Neurogenesis Druggability 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Drug Discovery medicine Animals Humans Neuroinflammation Pharmacology Neurons Leukotriene biology Cell Death business.industry Neurodegeneration Drug Repositioning medicine.disease Leukotriene signaling pathway 030104 developmental biology Drug development Blood-Brain Barrier 030220 oncology & carcinogenesis biology.protein business Neuroscience Signal Transduction |
| Zdroj: | Drug discovery today. 24(2) |
| ISSN: | 1878-5832 |
| Popis: | The underlying pathology of Alzheimer's disease (AD) is complex and includes, besides amyloid beta (Aβ) plaque depositions and neurofibrillary tangles, brain atrophy and neurodegeneration, neuroinflammation, impaired neurogenesis, vascular and blood-brain barrier (BBB) disruptions, neurotransmitter disbalances, and others. Here, we hypothesize that such complex pathologies can only be targeted efficiently through pleiotropic approaches. One interesting drug target is the leukotriene pathway, which mediates various aspects of AD pathology. Approaching this pathway at different levels with genetic and pharmacological tools demonstrated beneficial outcomes in several in vivo studies using different mouse models of AD. Here, we review the current literature on the leukotriene signaling pathway as a target for drug development in AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect